科研之友
微信
新浪微博
Facebook
分享链接
摘要
Anti-IgE (omalizumab) reduces the allergic airway inflammation by binding of circulating, free immunoglobulin E. This leads to a significant improvement of allergic asthma. Seven Phase III studies in juveniles and adults demonstrate that omalizumab offers an effective and safe, new therapeutic option in the treatment of severe persistent asthma, not sufficiently controlled by standard therapy according to recent guidelines. It appears that even with regard to cost-effectiveness omalizumab could be a valuable new therapeutic option in severe persistent asthma, providing a significant reduction of asthma symptoms, asthma medication, rate of asthma exacerbations and emergency treatment, and improvement of asthma-related quality of life. Severe adverse effects are very rare.
- 出版日期2007-9
